2023
634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)
Punekar S, Welling T, Randolph Hecht J, Molina J, Smith C, Garon E, Pia Morelli M, Fakih M, Kirtane K, Grierson P, Patel S, Lin Y, Kopetz S, Locke F, Ward J, Lozac’hmeur A, Frigault M, Nikiforow S, Weng W, Specht J, Dragovich T, Vong J, Mardiros A, Liechty K, Go W, Welch J, Ng E, Maus M, Maloney D, Simeone D. 634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH). 2023, a724-a725. DOI: 10.1136/jitc-2023-sitc2023.0634.Peer-Reviewed Original Research
2022
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar S, Velcheti V, Neel B, Wong K. The current state of the art and future trends in RAS-targeted cancer therapies. Nature Reviews Clinical Oncology 2022, 19: 637-655. PMID: 36028717, PMCID: PMC9412785, DOI: 10.1038/s41571-022-00671-9.Peer-Reviewed Original ResearchConceptsDuration of responseNovel combination therapiesCombination therapyClinical trialsTherapeutic strategiesSolid tumorsMutant KRASTumor microenvironmentDrug resistanceRAS pathwayCancer cellsDevelopment of inhibitorsCancer therapyOncogenic RASPatientsOncogenic proteinsTherapyKRASResistance mechanismsMutant isoformsInhibitorsRASMalignancyTumorsCancer
2021
Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer
Punekar S, Griffin M, Masri L, Roman S, Makarov D, Sherman S, Becker D. Socioeconomic Determinants of the Use of Molecular Testing in Stage IV Colorectal Cancer. American Journal Of Clinical Oncology 2021, 44: 597-602. PMID: 34753883, DOI: 10.1097/coc.0000000000000875.Peer-Reviewed Original ResearchConceptsStage IV colorectal cancerKRAS testingColorectal cancerMedicaid insuranceMultivariable-adjusted Cox proportional hazards modelsStage IV colorectal adenocarcinomaEpidermal growth factor receptor monoclonal antibodiesCox proportional hazards modelMultivariable logistic regression modelAdvanced colorectal cancerEnd Results (SEER) databaseRisk of deathReceptor monoclonal antibodyProportional hazards modelWild-type KRASSocioeconomic disparities persistLogistic regression modelsCRC patientsResults databaseColorectal adenocarcinomaKRAS mutationsHigher median household incomeHazards modelPatientsMolecular testingRole of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
Punekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAutoimmune conditionsDiscontinuation of ICIsPD-1/PD-L1Concurrent immune checkpoint inhibitorsImmune-related adverse eventsMetastatic renal cell carcinomaRole of IVIgUnderlying autoimmune conditionClasses of medicationsRenal cell carcinomaParaneoplastic dermatomyositisIntravenous immunoglobulinAdverse eventsPD-L1Antitumor responseCell carcinomaImmunomodulatory agentsMetastatic cancerImmune pathwaysExacerbationPatientsTreatmentCancer
2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database
Punekar S, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. American Journal Of Clinical Oncology 2020, 43: 846-849. PMID: 32910023, DOI: 10.1097/coc.0000000000000761.Peer-Reviewed Original ResearchConceptsG3 neuroendocrine tumorsColorectal neuroendocrine tumorsNeuroendocrine tumorsOverall survivalUnmarried patientsCox proportional hazards modelEnd Results (SEER) databaseGastrointestinal neuroendocrine tumorsPredictors of survivalPrognosis of patientsNational registry studyProportional hazards modelOlder patientsRegistry studySEER databaseWorse survivalMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsHazards modelPatientsSmall studyLogistic regressionChapter 4 Cancer Treatment-Related Thrombocytopenia
Punekar S. Chapter 4 Cancer Treatment-Related Thrombocytopenia. 2020, 17-20. DOI: 10.1016/b978-0-323-67241-2.00004-5.Peer-Reviewed Original Research
2019
Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.
Punekar S, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors. Journal Of Clinical Oncology 2019, 37: e15696-e15696. DOI: 10.1200/jco.2019.37.15_suppl.e15696.Peer-Reviewed Original ResearchOverall survivalNeuroendocrine tumorsCarcinoid tumorsSmall cell neuroendocrine tumorsCox proportional hazards modelColorectal carcinoid tumorsEnd Results (SEER) databaseDemographics of patientsPredictors of survivalColorectal neuroendocrine tumorsNew pathologic entityProportional hazards modelPatient demographicsMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsPathologic entityTumor gradeGI tractHazards modelPatientsSmall studyTumorsTreatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression
BECKER D, IYENGAR A, PUNEKAR S, NG J, ZAMAN A, LOEB S, BECKER K, MAKAROV D. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. Anticancer Research 2019, 39: 2467-2473. PMID: 31092441, DOI: 10.21873/anticanres.13366.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAbi/enzaCastration-resistant prostate cancerPSA progressionEnd of lifeProstate cancerVeterans AffairsOlder patientsBlack patientsClinical benefitClinical endpointsHospice servicesNational guidelinesPatientsEnza treatmentAdditional studiesProgressionENZAAbirateroneRegression analysisCancerTreatmentABIEnzalutamideEndpoint
2012
Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma
Friedberg J, Culligan M, Mick R, Stevenson J, Hahn S, Sterman D, Punekar S, Glatstein E, Cengel K. Radical Pleurectomy and Intraoperative Photodynamic Therapy for Malignant Pleural Mesothelioma. The Annals Of Thoracic Surgery 2012, 93: 1658-1667. PMID: 22541196, PMCID: PMC4394024, DOI: 10.1016/j.athoracsur.2012.02.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCohort StudiesCombined Modality TherapyDisease-Free SurvivalFemaleFollow-Up StudiesHumansImmunohistochemistryIntraoperative CareMaleMesotheliomaMiddle AgedNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPhotochemotherapyPleuraPleural NeoplasmsRisk AssessmentSurvival AnalysisTime FactorsTreatment OutcomeConceptsProgression-free survivalMacroscopic complete resectionRadical pleurectomyIntraoperative photodynamic therapyNonepithelial subtypeMedian survivalComplete resectionEpithelial subtypesStage III/IV diseaseMedian progression-free survivalStage III/IV cancerPhotodynamic therapyLung-sparing approachLung-sparing surgeryMalignant pleural mesotheliomaPostoperative mortalitySystemic therapyPleural mesotheliomaEpithelial diseasePatientsMesotheliomaSubtypesTherapyMonthsSurvival